ClinicalTrials.gg
RecruitingNCT06075433DAPTLongUpdated Feb 21, 2025

Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

An observational study in Coronary Artery Disease, Percutaneous Coronary Intervention and Dual Antiplatelet Therapy, sponsored by Genoss Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Genoss Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..

Started
2022
with 1 other
Observational
6 of 10
5 open now
Registered
6th of 10
by date

Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is one of 2 that started in 2022, is one of 6 observational ones, and was the 6th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Genoss Co., Ltd., or all of them as a file.
02

Study summary

The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.

Read the detailed description

The Genoss DES is a novel, biodegradable, polymer-coated, sirolimus eluting stent with a cobalt-chromium stent platform and thin strut. Although the efficacy and safety of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the objective of this prospective, multicenter study was to evaluate the clinical efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.

The Genoss DES registry is a prospective, single-arm, observational study for evaluation of clinical outcomes of 1 year duration of DAPT after Genoss DES implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure from 9 sites in South Korea. The primary endpoint was a deviceoriented composite endpoint (DOCE), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically indicated target lesion revascularization (TLR) at 12 months. The key secondary endpoint was a patient-oriented composite endpoint (POCE), defined as a composite of all-cause death, any myocardial infarction, and any revascularization at 12 months.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Dual Antiplatelet Therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with coronary artery disease treated with GENOSS DES

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of 19 and over
  2. Patients with coronary artery disease treated with GENOSS SES
  3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written as study participants

Exclusion criteria

Exclusion Criteria:

  1. Patients with cardiogenic shock at the time of hospitalization
  2. Patients who are pregnant or planning to become pregnant
  3. Patients with a of less than 1 year
  4. Patients participating in randomized controlled trials using other medical devices
  5. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • GENOSS Sirolimus Eluting Coronary Stent System

    Patients with coronary artery disease treated with the GENOSS DES \<Definition of a complex high-risk patients\> 1. Clinical factors * Age 75 or older * History of diabetes (those who have had diabetes in the past or are taking diabetes medication) * History of chronic kidney disease (GFR \<60ml/min/1.73m2) or dialysis * History of stroke * History of coronary artery bypass graft * Left ventricular dysfunction (LVEF \<40%) * Severe valve disease * Acute coronary syndrome with positive troponin levels 2. Lesion/procedure factors * Left main lesion * Chronic total occlusion * Bifurcation lesion with branches larger than 2 mm * Calcified lesion (moderate to severe calcified lesion) * Restenosis lesion (in-stent restenosis) * Multivessel PCI * Three or more stents implanted (≥3 stents implanted) * When the stent length of one lesion is more than 50 mm (total stent length \>50 mm in a lesion)

06

What researchers measure

Primary outcomes

  1. Device-oriented composite endpoint

    DOCE is defined as a composite of cardiac death, target vessel-related myocardial infarction (TV-MI) and clinically indicated target-lesion revascularization (TLR).

    Time frame: at 12 months after the procedure

Secondary outcomes

  1. Patient-oriented composite endpoint

    POCE is defined as a composite of all-cause death, any myocardial infarction, and any revascularization.

    Time frame: at 12 months after the procedure

  2. All-cause deaths

    Time frame: at 12 months after the procedure

  3. Cardiac death

    Time frame: at 12 months after the procedure

  4. Non-cardiac death

    Time frame: at 12 months after the procedure

  5. Any myocardial infarction

    Time frame: at 12 months after the procedure

  6. Target vessel-realted myocardial infarction (TV-MI)

    Time frame: at 12 months after the procedure

  7. Any revascularization

    Time frame: at 12 months after the procedure

  8. Revascularization of clinically appropriate target lesions

    Time frame: at 12 months after the procedure

  9. Stent thrombosis by ARC definition

    Time frame: at 12 months after the procedure

  10. Lesion success

    When the final residual lesion stenosis is less than 30% using any surgical method.

    Time frame: during the procedure

  11. Procedure success

    When the final residual lesion stenosis is less than 30% using any surgical method, and there is no post-procedure death, myocardial infarction, or revascularization during the hospitalization period.

    Time frame: immediately after the procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No The data set is available from the the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 67 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 10, 2023
StartActual
May 13, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06075433
Lead sponsor
Genoss Co., Ltd.
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
May 13, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 21, 2025

Study contacts

YoungJin Youn
Contact
younyj@yonsei.ac.kr
033-741-0910

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion